PineTree Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Science And Engineering
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mech
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 36
- Industries
- Biotechnology, Health Care, Science And Engineering
- Status
- Private
- Website
- pinetreetx.com
- Company page
Recent activity at PineTree Therapeutics
- : Pinetree Therapeutics has raised $47 million in an oversubscribed Series B round to advance next-generation protein degraders in oncology.
- : Pinetree Therapeutics, Inc. Secures $23.5 Million Of Series A1 Funding To Develop Cutting Edge Platform Technology To Create Therapeutic Assets For Unmet Medical Needs
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
PineTree Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Series B | $47.0M |
| Jun 2022 | Series A | $23.5M |
Leadership
- Ho-Juhn Song, CEO/Founder
- John Jia, Director
- Seulhee Kim, Doctor
- Donna Grant, Executive Director
Verified email and direct lines for PineTree Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
PineTree Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to PineTree Therapeutics
- Electra Therapeutics · Biotechnology, Health Care, Science And Engineering
- AN2 Therapeutics · Biotechnology, Health Care, Science And Engineering
- Saol Therapeutics · Biotechnology, Health Care, Science And Engineering
- Atavistik Bio · Biotechnology, Health Care, Science And Engineering
- Ray Therapeutics · Biotechnology, Health Care, Science And Engineering
About PineTree Therapeutics: questions and answers
What does PineTree Therapeutics do?
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mech
Where is PineTree Therapeutics headquartered?
PineTree Therapeutics is headquartered in Cambridge, Massachusetts, United States.
How many employees does PineTree Therapeutics have?
PineTree Therapeutics has about 36 employees.
Has PineTree Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for PineTree Therapeutics. The most recent, Series B of $47.0M, was in Oct 2025.
Who leads PineTree Therapeutics?
Ho-Juhn Song is a CEO/Founder at PineTree Therapeutics.
What is the latest news on PineTree Therapeutics?
On Oct 29, 2025, Pinetree Therapeutics has raised $47 million in an oversubscribed Series B round to advance next-generation protein degraders in oncology.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy